The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology
Open accessAbstract
Objective To evaluate whether APOE ε4 is associated with severity of Lewy body (LB) pathology, independently of Alzheimer disease (AD) pathology. Methods Six hundred fifty-two autopsy-confirmed LB disease (LBD) cases and 660 clinical controls were genotyped for APOE. In case-control analysis, LBD cases were classified into 9 different groups according to severity of both LB pathology (brainstem, transitional, diffuse) and AD pathology (low, moderate, high) to assess associations between APOE ε4 and risk of different neuropathologically defined LBD subgroups in comparison to controls. In LBD cases only, we also measured LB counts from 5 cortical regions and evaluated associations with ε4 according to severity of AD pathology. Results As expected, APOE ε4 was associated with an increased risk of transitional and diffuse LBD in cases with moderate or high AD pathology (all odds ratios ≥3.42, all p ≤ 0.004). Of note, ε4 was also associated with an increased risk of diffuse LBD with low AD pathology (odds ratio = 3.46, p = 0.001). In the low AD pathology LBD subgroup, ε4 was associated with significantly more LB counts in the 5 cortical regions, independently of Braak stage and Thal phase (all p ≤ 0.002). Conclusions Our results indicate that APOE ε4 is independently associated with a greater severity of LB pathology. These findings increase our understanding of the mechanism behind reported associations of ε4 with risk of dementia with Lewy bodies and Parkinson disease with dementia, and suggest that ε4 may function as a modifier of processes that favor LB spread rather than acting directly to initiate LB pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“APOEε4 has also been associated with the burden of α-synuclein inclusions in LBD with minimal AD co-pathology62,71, although other studies have only found an association between APOEε4 and LBD in the presence of AD neuropathology, but not in pure LBD72,73.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [62]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Specifically, APOEε4 carriage has been independently associated with increased odds and severity of Lewy body pathology49,62 and TDP-43 pathology59,63,64 and with the presence of TDP-43-related hippocampal sclerosis63 in the scenario of a primary neuropathological diagnosis of AD.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [62]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Self-citationMontine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
Self-citationDiagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499 · cited 1×
“Inferior parietal 0 (0, 40) 0 (0, 50) 18 (0, 50) 48 (3, 50) 50 (10, 50) 50 (0, 50) 50 (32, 50) 50 (4, 50) 50 (0, 50)”
Research works printed but not linked: 45
- 10.1097/00005072-199804000-00005 · DOI
- 10.1016/S1474-4422(09)70238-8 · DOI · Paper page
- 10.1212/WNL.0000000000004058 · DOI · Paper page
- 10.1001/archneur.59.1.102 · DOI
- 10.1097/NEN.0b013e31817d7a1d · DOI
- 10.1007/s00401-008-0344-8 · DOI
- 10.1016/j.parkreldis.2015.09.011 · DOI
- 10.1136/jnnp-2013-307228 · DOI
- 10.1212/WNL.0b013e3182a2cbd1 · DOI
- 10.1093/hmg/ddu334 · DOI · Paper page
- 10.1016/S1474-4422(17)30400-3 · DOI · Paper page
- 10.1001/jamaneurol.2013.600 · DOI · Paper page
- 10.1001/archneur.63.2.189 · DOI · Paper page
- 10.1002/ana.23659 · DOI · Paper page
- 10.1016/j.neulet.2006.12.008 · DOI
- 10.1016/j.nbd.2012.02.002 · DOI
- 10.1016/S1353-8020(13)70011-7 · DOI
- 10.1126/science.8346443 · DOI · Paper page
- 10.1073/pnas.90.20.9649 · DOI · Paper page
- 10.1073/pnas.90.5.1977 · DOI · Paper page
- 10.1038/nrneurol.2012.263 · DOI · Paper page
- 10.1126/science.1566067 · DOI · Paper page
- 10.1007/s00702-009-0240-y · DOI · Paper page
- 10.1016/S0733-8619(05)70232-2 · DOI
- 10.1097/01.jnen.0000225908.90052.07 · DOI · Paper page
- 10.1007/s00401-008-0345-7 · DOI · Paper page
- 10.1007/s00401-014-1302-2 · DOI
- 10.1093/brain/awv050 · DOI · Paper page
- 10.1097/00005072-198705000-00003 · DOI
- 10.1007/s004010051177 · DOI
- 10.1007/s00401-008-0409-8 · DOI · Paper page
- Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree—a new disease? Clin Neuropathol 1984;3:185–192.
- 10.1212/WNL.58.12.1791 · DOI · Paper page
- 10.1093/brain/awr031 · DOI
- 10.1016/j.parkreldis.2013.05.010 · DOI
- 10.1007/s00401-007-0336-0 · DOI
- 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.0.CO;2-E · DOI
- 10.1074/jbc.273.16.9443 · DOI
- 10.1016/j.parkreldis.2015.08.015 · DOI
- 10.1016/j.bbamem.2016.03.012 · DOI
- 10.7554/eLife.00592 · DOI
- 10.1007/s11010-008-0008-y · DOI
- 10.1111/j.1471-4159.2006.04348.x · DOI
- 10.1007/978-94-007-6331-9_2 · DOI
- 10.1016/j.mcn.2009.07.013 · DOI
Cited by
Sorted by citations
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
Self-citationAPOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30412-9 · Cited by 1,037
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
Self-citationDementia with Lewy bodies: an update and outlook
Outeiro, T. F., Koss, D. J., Erskine, D., Walker, L., Kurzawa-Akanbi, M., Burn, D., Donaghy, P., Morris, C., Taylor, J.-P., Thomas, A., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0306-8 · Cited by 381
Immune Signaling in Neurodegeneration
Hammond, T. R., Marsh, S. E., & Stevens, B. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.016 · Cited by 336
Multifaceted roles of APOE in Alzheimer disease
Jackson, R. J., Hyman, B. T., & Serrano-Pozo, A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00988-2 · Cited by 193
APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid
Zhao, N., Attrebi, O. N., Ren, Y., Qiao, W., Sonustun, B., Martens, Y. A., Meneses, A. D., Li, F., Shue, F., Zheng, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1809 · Cited by 156
Self-citationHuynh, T.-P. V., Wang, C., Tran, A. C., Tabor, G. T., Mahan, T. E., Francis, C. M., Finn, M. B., Spellman, R., Manis, M., Tanzi, R. E., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0337-1 · Cited by 139
LRP1 is a neuronal receptor for α-synuclein uptake and spread
Chen, K., Martens, Y. A., Meneses, A., Ryu, D. H., Lu, W., Raulin, A. C., Li, F., Zhao, J., Chen, Y., Jin, Y., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00560-w · Cited by 115
Self-citationThe cell biology of APOE in the brain
Windham, I. A., & Cohen, S. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.09.004 · Cited by 103
Wennberg, A. M., Whitwell, J. L., Tosakulwong, N., Weigand, S. D., Murray, M. E., Machulda, M. M., Petrucelli, L., Mielke, M. M., Jack, C. R., Knopman, D. S., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.01.008 · Cited by 79
Self-citationAssociation of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease
Qian, J., Betensky, R. A., Hyman, B. T., & Serrano-Pozo, A. (2021) · Neurology · doi:10.1212/wnl.0000000000011883 · Cited by 71
Shade, L. M. P., Katsumata, Y., Abner, E. L., Aung, K. Z., Claas, S. A., Qiao, Q., Heberle, B. A., Brandon, J. A., Page, M. L., Hohman, T. J., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01939-9 · Cited by 72
Self-citationStaurenghi, E., Leoni, V., Lo Iacono, M., Sottero, B., Testa, G., Giannelli, S., Leonarduzzi, G., & Gamba, P. (2022) · Antioxidants · doi:10.3390/antiox11112168 · Cited by 24
Current insights into apolipoprotein E and the immune response in Alzheimer's disease
Lin, P. B., & Holtzman, D. M. (2024) · Immunological Reviews · doi:10.1111/imr.13414 · Cited by 19
Metadata
- Authors
- Dickson, D. W., Heckman, M. G., Murray, M. E., Soto, A. I., Walton, R. L., Diehl, N. N., van Gerpen, J. A., Uitti, R. J., Wszolek, Z. K., Ertekin-Taner, N., Knopman, D. S., Petersen, R. C., Graff-Radford, N. R., Boeve, B. F., Bu, G., Ferman, T. J., & Ross, O. A.
- Affiliations
- Mayo Clinic (US)
- From the Department of Neuroscience (D.W.D., M.E.M., A.I.S., R.W., N.E.-T., G.B., O.A.R.), Division of Biomedical Statistics and Informatics (M.G.H., N.N.D.), and Departments of Neurology (J.A.v.G., R.J.U., Z.K.W., N.E.-T., N.R.G.-R.) and Psychiatry and Psychology (T.J.F.), Mayo Clinic, Jacksonville, FL; and Department of Neurology (D.S.K., R.C.P., B.F.B.), Mayo Clinic, Rochester, MN.
- ORCID
- Venue
- Neurology
- Published
- 2018-09-18
- Volume
- 91
- Issue
- 12
- Pages
- e1182-e1195
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC6161556
- OpenAlex
- W2888557643
- Cited by
- 210
- References
- 5
- Citations by year
- 2026: 18 · 2025: 39 · 2024: 28 · 2023: 20 · 2022: 30 · 2021: 27 · 2020: 26 · 2019: 21 · 2018: 1
- FWCI
- 12.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neurology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (R01AG015866, RF1AG051504, R01AG027924, U01AG045390, RF1AG046205, U01AG046139, R01AG046205, R01AG061796, R01AG035355, P50AG016574)
- National Institute of Neurological Disorders and Stroke (R01NS080820, R01NS078086, U54NS100693, P50NS072187, P01NS074969)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- APOE ε4, Lewy body pathology, Alzheimer disease pathology, dementia with Lewy bodies, Parkinson's disease dementia, genetic risk, Braak stages, cortical Lewy bodies
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Female, Genotype, Humans, Male, Case-Control Studies, Lewy Body Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
